CCDC58 is a potential biomarker for diagnosis, prognosis, immunity, and genomic heterogeneity in pan-cancer

Area of Science:

• Oncology
• Molecular Biology
• Bioinformatics

Background:

• Coiled-coil domain-containing 58 (CCDC58) is implicated in tumorigenesis across various cancers.
• A comprehensive pan-cancer analysis of CCDC58's roles in diagnosis, prognosis, and immune infiltration is lacking.

Purpose of the Study:

• To conduct a systematic pan-cancer analysis of CCDC58 expression, its correlation with clinical outcomes, and its role in the tumor immune microenvironment.
• To investigate the biological functions of CCDC58 in liver hepatocellular carcinoma (LIHC).

Main Methods:

• Utilized TCGA, GTEx, UALCAN, HPA, CancerSEA, BioGRID, GEPIA 2.0, TIMER 2.0, and TISIDB databases for expression and clinical data analysis.
• Assessed CCDC58's association with diagnosis, prognosis, genetic alterations, DNA methylation, genomic heterogeneity, and immune infiltration.
• Performed enrichment analysis and functional experiments in LIHC.

Main Results:

• CCDC58 is differentially expressed in most tumors, demonstrating significant diagnostic and prognostic value.
• CCDC58 expression correlates with genetic alterations, DNA methylation, and genomic heterogeneity in specific cancers.
• CCDC58 influences the tumor immune microenvironment and is linked to cell cycle and mitosis-related genes.

Conclusions:

• CCDC58 serves as a novel pan-cancer biomarker with potential as a therapeutic target for improving patient outcomes.
• CCDC58 plays a crucial role in tumor cell proliferation and migration, particularly in LIHC.